Previous 10 | Next 10 |
Lannett finds itself at a confluence of choices brought forth more by management than the macro-environment. With revenues sinking to new lows, investors are left wondering if management can find a path to the aspirational goal of $1 billion in revenues by 2025. With a share price...
Gainers: TDCX (NYSE:TDCX) +16%. ALJ Regional Holdings (NASDAQ:ALJJ) +8%. Nxt-ID (NASDAQ:NXTD) +8%. Microvast Holdings (NASDAQ:MVST) +7%. Archer Aviation (NYSE:ACHR) +7%. Losers: SkyWest (NASDAQ:SKYW) -21%. GrafTech International (NYSE:EAF) -9%. Alpine 4 Holdings (NASDAQ:AL...
Gainers: Snap (NYSE:SNAP) +52%. Bill.com Holdings (NYSE:BILL) +31%. Indonesia Energy Corporation (NYSE:INDO) +28%. eGain (NASDAQ:EGAN) +22%. Sphere (NASDAQ:ANY) +21%. Standard Lithium (NYSE:SLI) +17%. Aurora Innovation (NASDAQ:AUR) +17%. Unity Software (NYSE:U) +17%. Astria Therapeutics (NASD...
Lannett (LCI -27.5%) stock plummeted Feb. 4, after its Q2 results failed to beat analysts' estimates and a revised fiscal 2022 outlook. Q2 net sales declined to $86.5M, compared to $133.9M in Q2 fiscal 2021. "For the quarter, ongoing and increasing competitive pricing pressure across our...
Gainers: IRadimed IRMD +8%. Meridian Bioscience VIVO +8%. Biofrontera (NASDAQ:BFRI) +6%. Inspira Technologies Oxy (NASDAQ:IINN) +6%. Taysha Gene Therapies (NASDAQ:TSHA) +5%. Losers: Lannett Company (NYSE:LCI) -24%. Vanda Pharmaceuticals (NASDAQ:VNDA) -22%. E...
Lannett Company, Inc. (LCI) Q2 2022 Earnings Conference Call February 03, 2022 4:30 PM ET Company Participants Robert Jaffe – Investor Relations Tim Crew – Chief Executive Officer John Kozlowski – Chief Financial Officer Conference Call Participants Scott Henry – R...
Lannett press release (NYSE:LCI): Q2 Non-GAAP EPS of -$0.39 misses by $0.07. Revenue of $86.5M (-35.4% Y/Y) misses by $3.71M. Shares -16%. Adj. 2022 Guidance: Net sales: $335 million to $360 million, down from $370 million to $400 million vs. $389.69M consensus. Gross margin...
LANNETT REPORTS FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS; REVISES DOWN FULL-YEAR GUIDANCE -- Q2 Business and Financial Highlights: - Net Sales were $86.5 Million - Negative Adjusted EBITDA was $1.0 Million - Cash in Excess of $98 Million at December 31 - Nove...
LANNETT TO REPORT FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON THURSDAY, FEBRUARY 3 PR Newswire TREVOSE, Pa. , Jan. 27, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for ...
LANNETT ANNOUNCES FDA COMPLETES REVIEW OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE --FDA States Pivotal Clinical Trial May Proceed, Trial Expected to Commence By March 2022-- PR Newswire PHILADELPHIA , Jan. 21, 2022 /PRNewswi...
News, Short Squeeze, Breakout and More Instantly...
Lannett Co Inc Company Name:
LCI Stock Symbol:
NYSE Market:
NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS PR Newswire Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction ...
LANNETT SHARES UPDATE PR Newswire Announces Positive Results from Pivotal Clinical Insulin Trial that Demonstrates Biosimilarity to Reference Product Productive Conversations with Key Secured Creditors Toward a Balance Sheet Strengthening, Recapitalization or Res...